Novartis coasts towards first CAR-T approval
Unanimous recommendation for CTL019 ahead of October decision builds confidence in T-cell genetic reprogramming
The first cancer therapy based on the revolutionary CAR-T approach, which genetically reprograms patients’ own white blood cells, looks set for approval in the US in early October 2017.